ImClone/Bristol Aim To Expand Erbitux's Reach To Asia
This article was originally published in PharmAsia News
Executive Summary
ImClone and Bristol-Myers Squibb are attempting to make Erbitux (cetuximab) the first EGFR receptor-inhibiting monoclonal antibody to be available in Japan under a co-development and co-commercialization agreement with Merck KGaA announced Oct. 17